Evolution of platelet function in adult patients with chronic immune thrombocytopenia on romiplostim treatment

Br J Haematol. 2019 Oct;187(2):e38-e42. doi: 10.1111/bjh.16164. Epub 2019 Aug 18.

Authors

Anastasia A Ignatova¹, Irina A Demina¹, Vadim V Ptushkin², Svetlana G Khaspekova³, Olga N Shustova³, Maria M Pankrashkina², Aleksandr A Ryabykh^{1

4}, Sergei I Obydennyi^{1

5}, Olga S Strelkova⁴, Dmitry M Polokhov¹, Elena A Seregina¹, Aleksandr V Poletaev¹, Fazoil I Ataullakhanov^{1

4

5}, Igor I Kireev⁴, Alexei V Mazurov³, Alexei A Maschan¹, Galina A Novichkova¹, Mikhail A Panteleev^{1

4

5

6}

Affiliations

¹ Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Moscow, Russia.
² City Clinical Hospital Named After S.P. Botkin, Moscow, Russia.
³ National Medical Research Center for Cardiology, Moscow, Russia.
⁴ Lomonosov Moscow State University, Moscow, Russia.
⁵ Center for Theoretical Problems of Physicochemical Pharmacology, Moscow, Russia.
⁶ Moscow Institute of Physics and Technology, Dolgoprudny, Russia.

PMID: 31422582
DOI: 10.1111/bjh.16164

No abstract available

Keywords: bleeding risk; flow cytometry; immune thrombocytopenia; platelet function; romiplostim.

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Blood Platelets / metabolism*
Blood Platelets / pathology
Female
Humans
Male
Middle Aged
Purpura, Thrombocytopenic, Idiopathic / blood*
Purpura, Thrombocytopenic, Idiopathic / drug therapy*
Purpura, Thrombocytopenic, Idiopathic / pathology
Receptors, Fc / administration & dosage*
Recombinant Fusion Proteins / administration & dosage*
Thrombopoietin / administration & dosage*

Substances

Receptors, Fc
Recombinant Fusion Proteins
Thrombopoietin
romiplostim